Augustin Matthias, Radtke Marc A, Zschocke Ina, Blome Christine, Behechtnejad Julia, Schäfer Ines, Reusch Michael, Mielke Volker, Rustenbach Stephan Jeff
Department of Dermatology, German Center for Health Services Research in Dermatology (CVderm), University Clinics of Hamburg, 20246 Hamburg, Germany.
Arch Dermatol Res. 2009 Sep;301(8):561-71. doi: 10.1007/s00403-009-0928-8. Epub 2009 Mar 27.
Evaluation of therapeutic benefits from the patient's perspective is important in medical decision-making and reimbursement. This study aimed at developing and validating an instrument on patient-defined needs and benefits in dermatology. The questionnaire was developed according to international guidelines. The benefit assessment consists of two steps: before treatment, every patient defines his treatment needs according to a standardized list. After treatment, the patient rates the degree of benefits achieved. A "patient benefit index" (PBI) is calculated by averaging the preference-weighed results of all items. The PBI questionnaire was validated in a sample of 500 patients with ten skin diseases and in a treatment study on 906 patients with acne. The patients defined a broad spectrum of needs and treatment benefits, indicating disease-specific patterns. The PBI showed good feasibility, reliability (Cronbach's alpha >0.91) and construct validity, high responsiveness, and discrimination between subgroups. The PBI permits valid evaluation of patient-relevant benefits in dermatological treatment.
从患者角度评估治疗益处对于医疗决策和报销很重要。本研究旨在开发并验证一种关于皮肤科患者定义的需求和益处的工具。该问卷是根据国际指南制定的。益处评估包括两个步骤:治疗前,每位患者根据标准化列表确定其治疗需求。治疗后,患者对所取得的益处程度进行评分。通过对所有项目的偏好加权结果求平均值来计算“患者益处指数”(PBI)。PBI问卷在500例患有十种皮肤病的患者样本以及一项针对906例痤疮患者的治疗研究中得到了验证。患者确定了广泛的需求和治疗益处,显示出疾病特异性模式。PBI显示出良好的可行性、可靠性(Cronbach's alpha>0.91)和结构效度、高反应性以及亚组间的区分度。PBI能够对皮肤科治疗中与患者相关的益处进行有效评估。